European Chamber Co-organises EU-China Biopharmaceutical Innovation and Development Roundtable
2022-11-24 | All chapters
On 24th November 2022, the EU-China Biopharmaceutical Innovation and Development Roundtable took place using a hybrid format connecting Beijing and Brussels.
The roundtable, co-organised by the European Chamber and the China Society for Drug Regulation (CSDR), with the support from the European Federation of Pharmaceutical Industries and Associations (EFPIA), enabled an open dialogue on pro-innovation regulatory policies between representatives from the European pharmaceutical industry and the National Medical Products Administration (NMPA).
Zhao Junning, NMPA Deputy Commissioner, attended the roundtable and delivered the keynote speech. Joerg Wuttke, European Chamber President, Zhang Wei, CSDR President, and Olivier Charmeil, Chair of EFPIA International Board Sponsored Committee, also attended and delivered additional opening remarks and speeches.
Deputy Commissioner Zhao highlighted that Europe and China are committed to strengthening cooperation and dialogue on health and innovation, a bilateral cooperation priority highlighted at the 2022 EU-China Summit and the EU-China High-level Economic and Trade Dialogue.
The NMPA stated it will continue to deepen its participation in international regulatory cooperation, and to further enhance key regulatory policies, notably in relation to drug review and approval, global drug development, and drug risk management.
President Wuttke highlighted the importance of the roundtable and regulatory cooperation for promoting innovation in the pharmaceutical industry in both China and Europe. He said that the European pharmaceutical industry will continue to exchange and work with China, to bring innovative products to the China market, to ensure patients have access to the best treatments available.
Officials from the NMPA Department of Science, Technology and International Cooperation, Department of Policies and Regulations, Department of Drug Registration, Department of Drug Regulation, and Centre for Drug Evaluation presented China’s key pharmaceutical regulatory policy developments, and joined discussions with industry experts and representatives from EU member states’ embassies in China.
The European Chamber would like to thank Boehringer Ingelheim, Bristol-Myers Squibb, Lundbeck, Novartis, Roche and Sanofi for their contributions to this important event.
The EU-China Biopharmaceutical Innovation and Development Roundtable provided a platform for in-depth, transparent, open, and pragmatic dialogues between European pharmaceutical industry with Chinese regulators, paving the way towards further cooperation.
中国欧盟生物医药创新发展圆桌论坛召开
11月24日下午，中国欧盟生物医药创新发展圆桌论坛在北京和布鲁塞尔以线上线下方式召开。会议由中国欧盟商会和中国药品监督管理研究会联合主办，欧洲制药工业协会联合会（EFPIA）支持。国家药品监督管理局副局长赵军宁出席会议并讲话。
赵军宁表示，在今年的中欧领导人峰会和第九次中欧经贸高层对话上，中欧双方都再次重申，将在包括健康和创新在内的多个关键合作领域加强双边与多边合作。中欧双方在医药健康领域具有良好的合作基础和发展前景，推进双方合作有利于促进生物医药健康产业发展。
赵军宁强调，国家药品监督管理局将继续全面贯彻落实《国务院办公厅关于全面加强药品监管能力建设的实施意见》，进一步提高审评审批效率，促进全球药品同步研发，加强药品全生命周期的风险管理，切实保障公众用药安全，深入参与国际监管协调机制，提升监管国际化水平。期待中欧双方继续加强药品监管领域国际协作，深化生物医药领域的合作交流。
中国欧盟商会主席伍德克和中国药品监督管理研究会会长张伟分别代表主办方致辞，一致认为，本次论坛对促进中欧生物医药产业创新发展至关重要，中欧产业界将深化交流与合作，及时为中欧人民提供更高质量的创新产品。
论坛邀请国家药品监督管理局科技和国际合作司、政策法规司、药品注册管理司、药品监督管理司、药品审评中心有关同志分别就中国药品监管法规政策最新进展、生物药品审评审批制度改革进展、药品安全监管工作进展和药品变更管理法规进展以及展望未来加强国际监管合作等内容作了专题报告，并围绕相关行业热点问题与业界代表、欧盟成员国大使馆卫生参赞进行了深入交流探讨。中国药品监督管理研究会药品监管研究国际交流专业委员会主任委员薛斌主持会议。
来自勃林格殷格翰、百时美施贵宝、灵北、诺华、罗氏、赛诺菲的业界专家参加了讨论。
与会代表表示，本次圆桌论坛讨论深入、透明、开放、务实，各方均表达进一步合作的强烈愿望。与会代表认为，中国药品监管改革进步举世瞩目，在科学技术日新月异和医药全球化发展的形势下，中欧双方更应携手合作，共同面对疾病对人类健康的挑战，营造持续发展的良好生态环境。